NOC.US Weekly Report · 2026-W41
NOC shares rose 0.57% this week, extending recent downward momentum with the stock hitting a 52-week low. Valuations remain depressed at the 31.65th percentile of the 3-year range. A contradiction emerges: fundamentals are sound (Q2 revenue up 5%+), analyst consensus is decidedly bullish (14 strong buys vs 1 underperform), large institutional capital shows accumulation patterns, yet retail investors exit simultaneously and price action remains negative. This suggests the market is repricing growth expectations amid broader headwinds.
Price Action
Closing price at $480.72, up 0.57% from the prior week’s final trading day (2026-10-02 close of $478.00). Weekly trading range: high $486.935, low $471.355, intraweek volatility approximately 3.2%, reflecting a tight consolidation pattern.
Volume: approximately 4.629M shares traded across the five trading days, averaging 926K shares per day. This aligns with the 60-day median, indicating neither unusual accumulation nor distribution at the volume level.
Technical pattern: “consolidation after decline.” After Monday’s drop to $473.46, the stock reversed into a three-day recovery, closing Friday near the intraday high. Notably, the recovery lacked volume conviction—despite the rally, daily volumes remained unremarkable, suggesting a rebound without institutional sponsorship. The creation of a 52-week low this week underscores the break of previous support structures.
Valuation
NOC trades at 15.19x forward PE, positioning it at the 31.65th percentile within its 3-year range—meaning shares have traded below this valuation level only ~31% of the time over the past three years. Current valuation sits firmly in the bottom third of historical norms.
Peer comparison: The aerospace and defense sector (85 companies) median PE stands at 20.37x. NOC’s multiple trades ~25% below this median, ranking 2nd in the industry for relative cheapness. Book value multiple of 3.82x. From a pure valuation standpoint, NOC appears deeply discounted. Yet the market still reprices downward, implying investors are re-examining either growth trajectories or earnings power itself.
Earnings Delivery
Latest quarterly results (Q2 2026):
- EPS $7.68, down 5.77% YoY
- Sequential context: Q1 EPS $6.14; Q2 represents a 25% sequential gain despite the YoY decline
- Revenue $10.876B, up 5.07% YoY
- Net income $1.094B, down 6.81% YoY
- Net margin 10.06% (vs 8.86% in Q1), showing sequential margin expansion
Current consensus 2026E EPS stands at $29.14. With $14.42 already realized in H1 (Q1 $6.14 + Q2 $7.68), H2 needs to deliver approximately $14.72. Given historical YoY comparisons, Q3-Q4 likely faces headwinds. Q2 delivered top-line growth but net income declined, signaling margin compression from rising costs or operating expenses. The EPS shortfall aligns directionally with stock weakness, yet clashes with near-unanimous analyst optimism—a time lag that typically resolves through further data or sentiment shifts.
Capital Flows
Latest capital flow snapshot (2026-10-09) reveals stark polarization:
Large Institutional Capital: Inflow of 4.84 units against outflow of 0.85 units, netting +3.99 units. Large money is accumulating.
Mid-tier Capital: Inflow of 2.15 units against outflow of 4.87 units, netting -2.72 units. Mixed hands turning negative.
Retail Capital: Substantial outflow of 6.32 units (inflow 12.33 vs outflow 18.65). Retail investors are exiting steadily.
This split is the textbook signature of “smart money bottom fishing vs panic retail exodus.” Institutions perceive value at these prices and position accordingly, yet retail fear is still dominant. The divergence suggests institutional conviction about a valuation floor, though the absence of immediate retail follow-through means bottoming signals remain premature.
Analyst Consensus
Current rating distribution across 27 covering analysts:
- Strong Buy: 11
- Buy: 3
- Hold: 11
- Underperform: 1
- Sell: 0
Consensus rating: “Buy” with $623 price target, implying ~29.6% upside to current $480.72. Ratings updated as of October 9, 2026. The preponderance of Hold ratings and small Buy count suggests underlying reports may reflect earlier data snapshots, with limited incorporation of recent sharp declines. Citi’s rating “maintenance” (rather than upgrade) suggests defensive positioning—not a fresh conviction call.
This Week’s News
- Citi Remains a Buy on Northrop Grumman (NOC)
- Record backlogs, falling shares: the split screen in US defence
- GE Aerospace Soars Post-Split as B-21 Program Fuels Defense Sector Momentum
- Northrop Grumman says YFQ-48A Talon Blue completes first fully autonomous flight
- Weekly Recap | Northrop Grumman -6.37%, hitting a 52-week low
- Northrop Grumman Gets $18.8 Mln U.S. Army Contract For XRC Counter-UAS Program
- Missile Systems Surge 19% as Defense Contractors Navigate Geopolitical Shifts
- Pentagon’s $20.7B Missile Deal Fuels Defense Giants’ Record Backlogs
- Northrop Grumman awarded $111.4M U.S. Air Force contract modification
- AI’s Quiet Surge: Defense and Storage Firms Gain Traction
News Summary
Three narratives dominate NOC’s weekly headlines:
First, technological progress. The YFQ-48A Talon Blue autonomous flight completion marks incremental validation of NOC’s unmanned autonomy roadmap. FORTITUDE™ chip technology and GHOST-R satellite delivery for U.S. Space Force demonstrate diversification across aviation, satellite, and semiconductor domains within defense. Yet these announcements sparked minimal stock enthusiasm—investors appear to discount incremental tech wins against macro demand uncertainty.
Second, industry environment vs. relative performance divergence. The phrase “record backlogs, falling shares” encapsulates the paradox precisely. B-21 bomber drives the defense sector rally, missile orders surge 19%, $20.7B Pentagon contracts announced. Sector fundamentals are robust. Yet NOC underperforms peers week-to-week and hit a 52-week low. Investors appear skeptical about NOC’s specific participation or margin capture in this demand wave.
Third, relative weakness and defensive posturing. The stock underperformed Wednesday, hit 52-week lows intraweek, with analyst “maintenance” of buy ratings (rather than upgrades) signaling neither fresh conviction nor excitement.
Contradictions and Alignments
Central contradiction: Low valuation + strong ratings + institutional buying vs. persistent stock decline. PE ranks in the 31st percentile of 3-year history and trades 25% below sector median—objectively cheap by any standard. Analysts overwhelmingly positive (14 strong buy/buy vs 1 underperform), with $623 targets implying 30% upside. Large institutional capital accumulating. Yet shares push to 52-week lows and retail flees. The market is re-pricing. Likely catalysts: concern over mid-cycle growth trajectory (EPS YoY decline), sector-wide valuation compression, or macro headwinds (rates, commodities). The gap between valuation metrics and price action points to an earnings growth story the market does not yet believe.
Industry momentum vs. company earnings weakness: Pentagon orders accelerating, missile demand +19%, $20.7B in new contracts. Tailwind should lift all boats. Instead, NOC’s Q2 EPS fell 5.77% YoY and net income dropped 6.81% YoY, despite 5% revenue growth. Margin compression is evident. The divergence suggests either: (a) NOC incurs heavy front-end costs on large orders not yet recognized as revenue; (b) NOC’s share of the order flow is smaller than implied by headlines; or © competitive pricing pressure is eroding its margins. Investors may fear this boom does not translate to proportional NOC earnings growth.
Institutional conviction vs. retail panic: Large money buys, retail sells. This is a classic sign of either a genuine bottom forming or institutions being early/wrong. The absence of immediate sentiment reversal means the outcome remains genuinely uncertain—bottoms are not visible until after they occur.
Conclusion: NOC sits at the intersection of genuine value (valuation metrics, analyst view) and genuine uncertainty (earnings trajectory, retail capitulation). Institutional accumulation suggests confidence in a recovery, but the stock’s continued slide implies that confidence is not yet reflected in broad market behavior. The next catalyst will likely be Q3/Q4 earnings and 2027 guidance—moments that either confirm valuation support or deepen skepticism.